Meihong Wu

497 citations
21 papers · 362 indexed · h-index 11
Topics
Cancer Immunotherapy and Biomarkers (4 papers)MicroRNA in disease regulation (3 papers)Cancer Cells and Metastasis (3 papers)
Partner nations
ChinaUnited States

In The Last Decade

Meihong Wu

19 papers receiving 360 citations

Peers

Meihong Wu
Comparison fields: 5 of 67
  • Molecular Biology 167
  • Oncology 144
  • Cancer Research 106
  • Pulmonary and Respiratory Medicine 65
  • Immunology 50
Replace Benling Xu with:
Benling Xu China
Mototsugu Watanabe Japan
Xinquan Gu China
Huiyun Cai China
Carmela Paolillo Italy
Jadzia Tin-Tsen Chou Poland
Y Li China
Cigdem Ussakli United States
Meihong Wu relative to Benling Xu China Benling Xu's profile →
Citations per field
00.5×1.6×
Benling Xu · 1×
Citations per year

Countries citing papers authored by Meihong Wu

Since Specialization
Citations

This map shows the geographic impact of Meihong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meihong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meihong Wu more than expected).

Fields of papers citing papers by Meihong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meihong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meihong Wu. The network helps show where Meihong Wu may publish in the future.

Co-authorship network of co-authors of Meihong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Meihong Wu. A scholar is included among the top collaborators of Meihong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meihong Wu. Meihong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3
Autologous ex vivo expanded NK cells combined with PD-1 inhibitor improved ascitic fluid immune microenvironment of peritoneal metastatic pancreatic cancer: a case study.
2
4 6
5 2
6 30
7 12
8 17
9 11
10 33
11 28
12 91
13 26
14 4
15 20
16 11
17 7
18 4
19 5
20 0

About Meihong Wu

Meihong Wu is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 21 papers that have together received 362 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), MicroRNA in disease regulation (3 papers) and Cancer Cells and Metastasis (3 papers). The work is most often cited by research in Cancer Research (106 citations), Oncology (144 citations) and Molecular Biology (167 citations). Meihong Wu has collaborated with scholars based in China and United States. Frequent co-authors include Xianbao Zhan, Xiaobo Peng, Dan Feng, Bin Wang, Yingyi Zhang, Lixin Wang, Weiling Huang, Peng Fu, Linli Zhang and Jie Li. Their work appears in journals such as Journal of Clinical Oncology, Carcinogenesis and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026